Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

A.J. Coles, C.L. Twyman, D.L. Arnold, J.A. Cohen, C. Confavreux, E.J. Fox, H.P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, T. Miller, E. Fisher, R. Sandbrink, S.L. Lake, D.H. Margolin, P. Oyuela, F. Barkhof, M.A. Panzara, D. Compston

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1829-1839
JournalLancet
Volume380
Issue number9856
DOIs
Publication statusPublished - 2012

Cite this

Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., ... Compston, D. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, 380(9856), 1829-1839. https://doi.org/10.1016/S0140-6736(12)61768-1